Compare Mesoblast Limited (MESO) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Invesco Solar ETF — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Invesco Solar ETF trades at $43.46 (market cap $911.39M). The key difference: Mesoblast Limited is the larger of the two by market cap, and Invesco Solar ETF is more actively traded (983,074 versus 240,620). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Invesco Solar ETF for 34 Days on average.
| MESO | TAN | |
|---|---|---|
Market Cap | $1.81B | $911.39M |
Volume | 240,620 | 983,074 |
Sector | Health | Sector/Thematic |
52-Week High | $20.96 | $73.95 |
52-Week Low | $13.19 | $43.00 |
Typical Hold Time | 14 Days | 34 Days |
Enterprise Value | $1.89B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
TAN (Invesco Solar ETF) trades at $43.53, down 1.96% amid sector-wide pressure from high borrowing costs impacting solar project financing. Technical indicators show a bearish trend with strong sell signals from moving averages, while oscillators remain neutral. Recent news highlights solar stocks facing headwinds from interest rate sensitivity and market saturation concerns, though long-term growth drivers from energy transition remain intact.
The ETF faces near-term challenges from financing costs and competitive pressures, but maintains strategic positioning in the growing solar energy sector. Investors should weigh volatility risks against potential policy tailwinds and increasing global renewable energy adoption for long-term growth opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
